Tumor-promoting immune cells retrained to fight most aggressive type of brain cancer
Glioblastomas (GBM) are frequently resistant to immunotherapy. We showed that targeting regulatory T cells (Tregs) with an agonistic anti-GITR antibody reprograms tumor-infiltrating Tregs to effector cells, overcoming response to PD1 blockade in preclinical models of GBM.
Overcoming cancer drug resistance by blocking the production of mitochondrial ATP that fuels drug efflux pumps
The presence of drug efflux pumps that prevent drug accumulation in chemoresistant cancer cells is a cause of cancer treatment failure. We show that these drug pumps need mitochondrial ATP as fuel and that blocking mitochondrial ATP production with novel MCJ mimetics overcomes cancer chemoresistance
Behind the manuscript AL amyloidosis
1 of the major un met need for patients with amyloidosis is earlier diagnosis. Currently 30% of patients succumb to the disease within the 1st year following diagnosis. This is because the diagnosis is delayed due to failure recognize.
Artificial Intelligence, Cancer, and Azithromycin
The explosion of available data and revolution in algorithms have created a moment with infinite potential.
Decrypting the code of chromosome 1q abnormalities in multiple myeloma
One of the most common cytogenetic abnormalities in myeloma is one of the most widely debated and poorly understood. We have summarized the literature of this mysterious genomic aberration and call for standardization as a key to understanding the significance of +1q and improving patient outcomes.
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
Digital Display Precision Predictor (DDPP) is potentially a new global biomarker model that can apply to any type of drug alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer.
